A COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN PORTUGAL

被引：0
|
作者：
Pinheiro, B. [1 ]
Cardoso, M. [1 ]
Borges, M. [2 ]
Launonen, A. [3 ]
Ho, R. [3 ]
Miguel, Silva L. [1 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, P-11 Lisbon, Portugal
[2] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA56
引用
收藏
页码：S43 / S44
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of rituximab in treatment of diffuse large B-cell lymphoma.
    Coiffier, B
    Best, JH
    Omnes, LF
    Hornberger, JC
    BLOOD, 2001, 98 (11) : 864A - 864A
  • [42] Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands
    Groot, MT
    Lugtenburg, PJ
    Hornberger, J
    Huijgens, PC
    Uyl-de Groot, CA
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (03) : 194 - 202
  • [43] Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
    Anderson, Kara
    Shehata, Mena
    Singh, Davinder
    Al-Ourani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [44] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Sehn, Laurie H.
    Matasar, Matthew J.
    Flowers, Christopher R.
    Kamdar, Manali
    McMillan, Andrew K.
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Croft, Brandon
    Hirata, Jamie
    Cheng, Ji
    Ku, Grace
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [45] Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab Plus Bendamustine in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single Center Analysis of Pola Compassionate Use Program (CUP) in China
    Yang, Tao
    Li, Jun
    Zhang, Lingqian
    Hu, Renzhi
    Wu, Jing
    Ding, Yao
    Liang, Xiping
    Quan, Xi
    Hu, Chongling
    Zhang, Wenjun
    Guo, Bingling
    Wang, Chaoyu
    Li, Qiying
    Li, Jieping
    Nan, Yingyu
    Xiang, Ying
    Liu, Yao
    BLOOD, 2022, 140 : 12139 - 12139
  • [46] MODELING APPROACHES IN COST-EFFECTIVENESS ANALYSES OF CELL THERAPIES FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Hernandez, L. G.
    Martin, A. L.
    Brouwer, E. S.
    Chun, D.
    Cheng, L., I
    Bernhardt, A.
    VALUE IN HEALTH, 2022, 25 (01) : S53 - S53
  • [47] Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis
    Jung Yong Hong
    Dok Hyun Yoon
    Cheolwon Suh
    Won Seog Kim
    Seok Jin Kim
    Jae-Cheol Jo
    Jin Seok Kim
    Won-Sik Lee
    Sung Yong Oh
    Yong Park
    Sung-Yong Kim
    Mark Hong Lee
    Ho Sup Lee
    Young Rok Do
    Annals of Hematology, 2018, 97 : 1437 - 1443
  • [48] Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
    Kambhampati, Swetha
    Saumoy, Monica
    Schneider, Yecheskel
    Pak, Stacy
    Budde, Lihua Elizabeth
    Mei, Matthew G.
    Siddiqi, Tanya
    Popplewell, Leslie L.
    Wen, Yi-Ping
    Zain, Jasmine
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Danilov, Alexey V.
    Herrera, Alex F.
    Thiruvengadam, Nikhil R.
    BLOOD, 2022, 140 (25) : 2697 - 2708
  • [49] Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis
    Hong, Jung Yong
    Yoon, Dok Hyun
    Suh, Cheolwon
    Kim, Won Seog
    Kim, Seok Jin
    Jo, Jae-Cheol
    Kim, Jin Seok
    Lee, Won-Sik
    Oh, Sung Yong
    Park, Yong
    Kim, Sung-Yong
    Lee, Mark Hong
    Lee, Ho Sup
    Do, Young Rok
    ANNALS OF HEMATOLOGY, 2018, 97 (08) : 1437 - 1443
  • [50] Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Shi, Yuanfei
    Xu, Yi
    Wang, Jinghan
    Zheng, Xiaolong
    Li, Xueying
    Jin, Jie
    Tong, Hongyan
    Xie, Wanzhuo
    BLOOD, 2023, 142
12345